BioStock: Dicot’s CEO on TO4 and preparations for phase I

In August the pharmaceutical company Dicot will take a decisive step in its development. The plan is to initiate the clinical phase I study with the drug candidate LIB-01. Prior to this, the exercise of the warrant TO4 is currently ongoing and BioStock talked to CEO Elin Trampe about her reflections.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/06/dicots-ceo-on-to4-and-preparations-for-phase-i/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se